JP2023011601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023011601A5 JP2023011601A5 JP2022161758A JP2022161758A JP2023011601A5 JP 2023011601 A5 JP2023011601 A5 JP 2023011601A5 JP 2022161758 A JP2022161758 A JP 2022161758A JP 2022161758 A JP2022161758 A JP 2022161758A JP 2023011601 A5 JP2023011601 A5 JP 2023011601A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- histidine
- polypeptide
- seq
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500649P | 2017-05-03 | 2017-05-03 | |
| US62/500,649 | 2017-05-03 | ||
| JP2019560087A JP7157082B2 (ja) | 2017-05-03 | 2018-05-03 | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560087A Division JP7157082B2 (ja) | 2017-05-03 | 2018-05-03 | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023011601A JP2023011601A (ja) | 2023-01-24 |
| JP2023011601A5 true JP2023011601A5 (cg-RX-API-DMAC7.html) | 2023-07-06 |
| JP7442595B2 JP7442595B2 (ja) | 2024-03-04 |
Family
ID=62223280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560087A Active JP7157082B2 (ja) | 2017-05-03 | 2018-05-03 | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 |
| JP2022161758A Active JP7442595B2 (ja) | 2017-05-03 | 2022-10-06 | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560087A Active JP7157082B2 (ja) | 2017-05-03 | 2018-05-03 | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200129595A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3618809A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7157082B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102838263B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110621302A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018261154B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3062797A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL270233B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012506A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909709SA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI897843B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018204617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
| CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
| TW202432577A (zh) * | 2023-02-10 | 2024-08-16 | 美商拜奧海芬治療學有限公司 | 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀 |
| WO2025177263A1 (en) * | 2024-02-25 | 2025-08-28 | Biohaven Therapeutics Ltd. | Myostatin-binding proteins |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| US20030191187A1 (en) * | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| AU2008345424A1 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| EP2247615B1 (en) * | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| CN102076713B (zh) | 2008-05-02 | 2015-03-25 | 诺华股份有限公司 | 改进的基于纤连蛋白的结合分子及其用途 |
| AR071874A1 (es) * | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| PE20130041A1 (es) * | 2010-02-18 | 2013-01-28 | Bristol Myers Squibb Co | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| EP3091028A1 (en) * | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014015027A1 (en) * | 2012-07-18 | 2014-01-23 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
| US11173805B2 (en) * | 2018-01-30 | 2021-11-16 | Karma Automotive Llc | State-of-charge display system |
-
2018
- 2018-05-02 TW TW107114893A patent/TWI897843B/zh active
- 2018-05-03 CN CN201880029635.0A patent/CN110621302A/zh active Pending
- 2018-05-03 JP JP2019560087A patent/JP7157082B2/ja active Active
- 2018-05-03 KR KR1020247022666A patent/KR102838263B1/ko active Active
- 2018-05-03 IL IL270233A patent/IL270233B2/en unknown
- 2018-05-03 AU AU2018261154A patent/AU2018261154B2/en active Active
- 2018-05-03 CA CA3062797A patent/CA3062797A1/en active Pending
- 2018-05-03 SG SG11201909709S patent/SG11201909709SA/en unknown
- 2018-05-03 KR KR1020197035212A patent/KR102683806B1/ko active Active
- 2018-05-03 MX MX2019012506A patent/MX2019012506A/es unknown
- 2018-05-03 EP EP18726649.9A patent/EP3618809A1/en active Pending
- 2018-05-03 US US16/607,688 patent/US20200129595A1/en not_active Abandoned
- 2018-05-03 IL IL305625A patent/IL305625B2/en unknown
- 2018-05-03 WO PCT/US2018/030851 patent/WO2018204617A1/en not_active Ceased
-
2022
- 2022-10-06 JP JP2022161758A patent/JP7442595B2/ja active Active
-
2024
- 2024-07-16 AU AU2024204870A patent/AU2024204870B2/en active Active
-
2025
- 2025-04-30 US US19/194,765 patent/US20260069662A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10098876B2 (en) | Treating sexual desire disorders with flibanserin | |
| KR102664288B1 (ko) | 카파 오피오이드 수용체 효능제의 경구 제형 | |
| RU2384333C2 (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
| JP2024160287A5 (cg-RX-API-DMAC7.html) | ||
| US20050277629A1 (en) | Methods for the treatment of synucleinopathies (Lansbury) | |
| US8759400B2 (en) | Histone deacetylase inhibitors for enhancing activity of antifungal agents | |
| CN114727999A (zh) | 用于预防hiv的衣壳抑制剂 | |
| JP2024156754A5 (cg-RX-API-DMAC7.html) | ||
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| CN108347929A (zh) | 用于治疗疱疹病毒诱导的病况的方法和组合物 | |
| JP2025163108A5 (cg-RX-API-DMAC7.html) | ||
| US20100273868A1 (en) | R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma) | |
| JP2023518066A5 (cg-RX-API-DMAC7.html) | ||
| JP2023076632A5 (cg-RX-API-DMAC7.html) | ||
| JP7610410B2 (ja) | 副甲状腺ホルモンアナログの経口製剤および治療 | |
| CN1324607A (zh) | 用于指甲和周围组织真菌感染局部治疗的抗真菌剂和溶角蛋白剂的可控释放系统 | |
| JP2024522817A5 (cg-RX-API-DMAC7.html) | ||
| JP2022028975A5 (cg-RX-API-DMAC7.html) | ||
| PE20080233A1 (es) | Suspension acuosa estable antiinflamatoria | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| JP4812225B2 (ja) | 生理活性ペプチド含有腸溶性製剤 | |
| MX9704079A (es) | Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores. | |
| NO321151B1 (no) | Anvendelse av 2-amino-6-n-propyl-4,5,6,7-tetrahydrobenzotiazol, dets (-)-enantiomer eller et farmasoytisk akseptabelt salt av disse, for fremstilling av et medikament for behandling av "restless leg"- syndromet hos en pasient som lider eller mistenkes a ha denne tilstand | |
| JP2011084581A (ja) | 経鼻投与用医薬組成物 | |
| JP2022521266A5 (cg-RX-API-DMAC7.html) |